Catherine Coombs, MD, University of North Carolina, Chapel Hill, NC, compares the mechanism of action (MOA) of covalent vs non-covalent BTK inhibitors, explaining how their distinct MOA may impact resistance to treatment. The Phase I/II BRUIN trial (NCT03740529) has reported promising results for the non-covalent BTK inhibitor pirtobrutinib in terms of safety and efficacy and this drug is now being evaluated in Phase III studies both in frontline and relapsed/refractory (R/R) CLL. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.